Clinical Trial Results:
A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy
|
Summary
|
|
EudraCT number |
2004-002203-32 |
Trial protocol |
DE AT BE GB HU IT |
Global completion date |
17 Dec 2010
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Feb 2016
|
First version publication date |
18 Jul 2015
|
Other versions |
|
Summary report(s) |
2004-002203-32_XRP6976J_3501 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.